In 2011, Long and colleagues found that BRAF mutations were related to a high incidence of melanoma, including earlier age of onset, shortened survival, and lack of chronic skin damage, suggesting the importance of inhibiting mutated BRAF in a population of 197 patients [60]. The gene discussed is BRAF; the disease is melanoma.